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Summary
Objective: The vanilloid receptor transient receptor potential vanilloid 1 (TRPV1), expressed by sensory neurons that innervate joints, is
implicated in arthritis but the mechanisms are not fully understood. One possibility is that downstream effects of activation of TRPV1 are
mediated by the extracellularly-regulated kinase (ERK). ERK is phosphorylated (p-ERK) in sensory neurons in response to noxious stimuli
and its inhibition has been found to be antinociceptive in several pain models. We here wanted to ascertain whether TRPV1 may contribute
to the pain hypersensitivity and inﬂammation of arthritis via an ERK-mediated pathway.
Methods: We used a model of adjuvant-induced arthritis (AIA) of the ankle and investigated the changes in expression of p-ERK in sensory
afferent neurons in dorsal root ganglia (DRG) and spinal dorsal horn of TRPV1-knockout (KO) mice, compared to wild-type (WT) mice of the
same genetic background, using multiple immunoﬂuorescence.
Results: Two to three weeks after inducing AIA in mice, the number of neurons in DRG and spinal cord that expressed p-ERK was signiﬁcantly
higher on the side of AIA than on the contralateral, vehicle-injected side. The fraction of p-ERK-positive neurons in the DRG that also expressed
TRPV1 was increased, indicating that activation of ERK occurred preferentially in TRPV1-positive neurons. Moreover, TRPV1-KO mice had
reduced activation of ERK in sensory neurons, compared to WT mice. These changes in expression of p-ERK correlated with changes in
pain behavior and joint histopathology: TRPV1-KO mice had reduced nociceptive behavior and severity of arthritis, compared to WT mice.
Conclusion: Our results support the idea that activation of ERK in primary afferent neurons is mediated, at least in part, by TRPV1. In the
absence of TRPV1, the signs of arthralgia and histopathology in the mouse model of AIA are reduced. We conclude that TRPV1, expressed
by neurons in the articular afferent pathway, contributes to the pathogenesis of arthritis via an ERK-mediated pathway.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Pain is the primary complaint, the main cause for disability,
and the main therapeutic target in patients with osteoarthri-
tis (OA). The other two pathogenetic components of
arthritis, inﬂammation and progressive degeneration of joint
tissues, appear to be related to the pain’s severity, evolution
and prognosis, and may share common mechanisms with it.
An important step for our understanding of articular
nociception has been the cloning of the transient receptor
potential vanilloid 1 (TRPV1). TRPV1, a non-selective cation
channel, is activated by heat or Hþ as well as by vanilloids,
like capsaicin1. TRPV1 is synthesized in sensory neurons
in the dorsal root ganglia (DRG) and transported along their
peripheral axons to both skin and viscera, and centrally to
the spinal dorsal horn2,3. TRPV1 in the skin is important for
thermal nociception and inﬂammatory hyperalgesia and
allodynia, and has also been implicated in neuropathic pain4.aEqual contribution by these authors.
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244Besides the skin, TRPV1-positive sensory afferents may
innervate many deep structures of the body5,6. The expres-
sion of TRPV1 in articular afferents has been suggested by
immunostaining of nerve ﬁbers within the rat temporoman-
dibular joint7,8, rat and human knee joints9, and mouse
knee and ankle joints10. TRPV1 has also been demon-
strated in synovial ﬁbroblasts from patients with OA and
rheumatoid arthritis, suggesting that it may play a role in
non-neuronal modulation of nociception in arthritis11,12.
The involvement of TRPV1 in the mechanisms of joint
disease was proposed long before the receptor was ﬁrst
cloned, based on experiments with capsaicin, to which it
is the only known receptor13. Capsaicin is the active ingre-
dient of numerous preparations sold for relief of arthritic
pain; the efﬁcacy of these products is presumably based
on capsaicin’s ability to temporarily desensitize TRPV114.
Capsaicin-sensitive afferents have also been implicated in
experimental arthritis15,16.
More recently, knockout (KO) mice have been used to
investigate the role of TRPV1 in acute and chronic nocicep-
tion using several models of painful inﬂammatory conditions,
including arthritis17. The severity of adjuvant-induced arthritis
(AIA) of the knee18,19 and ankle20 was found to be signiﬁ-
cantly reduced in TRPV1-KO mice. Also, intraarticular
injections of capsaicin demonstrated signiﬁcant attenuation
of the articular vasoconstriction and reduction of blood ﬂow
245Osteoarthritis and Cartilage Vol. 17, No. 2in the knee of KO mice, indicating that these effects are
TRPV1-dependent21.
Although TRPV1 has been implicated in arthritis, the
mechanisms are not fully understood. Pain causes expres-
sion of immediate early genes in sensory neurons. The
biochemical link connecting activity in nociceptors to altered
gene expression remains unclear, but one important
element may be the ERK pathway. The extracellularly-
regulated kinase (ERK), a member of the mitogen-activated
protein kinase (MAPK) family of serine/threonin protein
kinases, transduces extracellular stimuli into intracellular
post-translational and transcriptional responses. When acti-
vated by mitogens, growth factors, and mediators of stress
and inﬂammation, MAPK is translocated to the nucleus and
regulates transcription of genes relevant to cellular activa-
tion, proliferation, and production of cytokines and other
factors, released during inﬂammation22,23. MAP kinases
exist in multiple isoforms and are activated by a series of
upstream kinases thus forming a biochemical cascade of
critical importance for the regulation of the inﬂammatory
process24,25.
ERK is phosphorylated (p-ERK) in sensory neurons in
response to noxious, but not to non-noxious, stimuli applied
to the skin or viscera26,27. Importantly, inhibition of ERK has
been found to be antinociceptive in several pain mod-
els28e30, suggesting that rather than merely providing a con-
venient experimental probe, this pathway may be an
essential link in the biochemical cascade of pain. Recently,
it was shown that an intraperitoneal application of an ERK in-
hibitor reduced capsaicin-induced thermal hyperalgesia
while intrathecal application of this inhibitor reduced release
of the neuropeptide calcitonin gene-related peptide (CGRP)
in skin31, and attenuated visceral pain behavior27. This sug-
gests that ERK plays a role in the development of hyperalge-
sia, exerting effects both centrally and peripherally.
Phosphorylation of ERK is required for the rapid facilitation
of heat-induced currents in sensory neurons that are thought
to be at the base of the mechanism of thermal hyperalge-
sia32, and for the upregulation of TRPV1 expression in sen-
sory neurons by cytokines33. A role for ERK has recently
been proposed also in arthritis: inhibition of the ERK pathway
has resulted in attenuated nociceptive behavior and inﬂam-
mation in models of arthritis in rats34,35 and mice25,36,37.
The goal of the present study was to ascertain whether
TRPV1 may contribute to the pain hypersensitivity and
inﬂammation of arthritis via an ERK-mediated pathway.
For this, we used ankle injections of complete Freund’s
adjuvant (CFA, known to cause arthralgia and arthritis)
and investigated the changes in expression of p-ERK in
the sensory afferents of TRPV1-KO, compared to wild-
type mice (WT) of the same genetic background. We
hypothesized that phosphorylation of ERK in articular affer-
ents is downstream to the activation of TRPV1 receptor. If
conﬁrmed, this would provide a mechanism for activation
of the ERK signaling cascade with the ensuing changes
in expression of genes for relevant receptors and media-
tors. In turn, this may underlie the sensitization, both periph-
eral and central, which is a major contributor to the pain and
inﬂammation in arthritis.Materials and methodsANIMALSA total of 31 male mice, including 14 TRPV1-KO and 17 wild-type C57BL/
6 mice (Jackson), weighing 25e30 g, were used in this study. Experimental
procedures were carried out in compliance with the NRC’s Guide for the
Care and Use of Laboratory Animals, according to a protocol approved bythe Institutional Animal Care and Use Committee at the University of North
Carolina.INDUCTION OF ARTHRITISMice were anesthetized with a mixture of 90 mg/kg ketamine and 10 mg/
kg xylazine and injected with 10 ml of CFA (20 mg/ml suspension of heat-
killed Mycobacterium tuberculosis in vehicle, Difco Lab) in each of two sites,
front and back of the left ankle, using a 30-gauge needle attached to a 10 ml
Hamilton syringe. The right ankle of each mouse was injected with the same
volume of vehicle (parafﬁn oil containing mannide monooleate; incomplete
Freund’s adjuvant, IFA). Matching numbers of KO and WT mice were sacri-
ﬁced at 3 days (n¼ 4), 7 days (n¼ 4), 14 days (n¼ 8), and 21 days (n¼ 12)
after induction of AIA; three WT mice without injections were sacriﬁced for
counts of DRG neurons in na€ıve animals.ASSESSMENT OF PAIN BEHAVIORSix each of the KO and WT mice were tested for pain behavior at various
time points after induction of AIA. Mice were acclimated unrestrained in
testing chambers, 2e3 times for 30e60 min prior to testing and nociceptive
sensitivity was assessed 2 days and 1 day before induction of AIA (baseline),
and then on days 3, 7, 10, 14, and 21 after induction of AIA. On each test
day, unilateral von Frey monoﬁlament test38 was conducted twice with
a Hargreaves radiant heat test39 between the two tests separated by
40 min intervals.
Withdrawal thresholds to tactile stimulation were measured using a stan-
dard set of von Frey monoﬁlaments (North Coast Medical Inc.). Each hind-
paw was stimulated ﬁve times for 1 s with a 1 s inter-stimulus interval
using ﬁlaments of increasing bending force (0.008, 0.02, 0.04, 0.07, 0.16,
0.4, 0.6, 1, 2, and 4 g), beginning with the lowest. The threshold for mechan-
ical sensitivity was recorded as the bending force of the ﬁlament that elicited
withdrawal response to three out of ﬁve presentations.
The latency to withdrawal from a thermal stimulus was measured using
the Hargreaves method with a Model 336 Paw/Tail Stimulator Analgesia
Meter (IITC) set at 2% idle light intensity and 40% working light intensity.
The stimulus was turned off manually upon the hindpaw withdrawal or auto-
matically if the 20 s cut-off time was reached. Each mouse received two trials
of each hindpaw with 10 min between trials and the results were averaged
for analysis. Data were expressed as the latency to withdrawal in seconds.
An overall mean of post-baseline behavioral data obtained from each test
across time was calculated for each of the WT and KO groups.TISSUE PROCESSINGMice anesthetized with sodium pentobarbital (80 mg/kg, i.p.) were per-
fused intracardially with 30 ml freshly prepared solution of 1% paraformalde-
hyde in 0.1 M phosphate buffer, pH 7.4 (PB), followed by 100 ml solution of
4% paraformaldehyde in PB. Tissues, including the L4eL5 spinal cord seg-
ments, corresponding DRG bilaterally, and ankle joint preparations, were
dissected out, post-ﬁxed in 4% paraformaldehyde for 4 h, and stored in
PB. Joint preparations were decalciﬁed in Rapid Cal Immuno (BBC Biochem-
ical) for 3 days. Tissue blocks were further cryoprotected in 30% sucrose in
PB for 24e48 h and sectioned on a cryostat. Sections of DRG (10 mm) and
joint preparations (20 mm) were thaw-mounted onto slides. Spinal cord was
cut at 30 mm and free-ﬂoating sections were collected in PB.IMMUNOHISTOCHEMISTRYSections of spinal cord and DRG were permeabilized with 50% ethanol in
phosphate-buffered saline (PBS; 0.01 M, pH 7.4) for 30 min, blocked with
10% normal donkey serum (NDS; Jackson) in PBS, and incubated overnight
with primary antibodies in PBS: rabbit anti-p-ERK (1:100, Cell Signaling), goat
anti-TRPV1 (1:250, Santa Cruz), and mouse anti-NeuN (1:100, Millipore). Af-
ter several rinses with PBS and incubation with 2% NDS for 30 min, sections
were incubated with the appropriate secondary antibodies (ﬂuorescein isothio-
cyanate- or Cy3-conjugated donkey antibodies; 1:200 in PBS; Jackson) for
2 h, rinsed, mounted, and coverslipped with Vectashield (Vector). Digital mi-
crographs were obtained with a Retiga EX cooled CCD camera (Q-Imaging)
attached to a Leitz DMR microscope and saved as TIFF ﬁles; contrast and
brightness were adjusted with Adobe Photoshop CS2.
All antibodies employed here are well characterized and in routine use in
our laboratory. As a matter of control, we processed sections of DRG and
spinal cord according to the above protocols, except that primary or second-
ary antibodies were omitted, or blocking peptides were added. Omission of
primary or secondary antibodies or preadsorption with appropriate blocking
peptides completely abolished speciﬁc staining. We also stained sections
of DRG and spinal cord for TRPV1 to verify genotype: staining of material
from KO mice was uniformly negative.
246 Y. Chen et al.: Vanilloid receptor TRPV1-mediated phosphorylation of ERKASSESSMENT OF ARTHRITIS0
0.5
1
1.5
2
2.5
12
0 3 7 10 14 21
M
e
c
h
a
n
i
c
a
l
 
t
h
r
e
s
h
o
l
d
 
(
g
)
A
B
WT-CFA
KO-IFAKO-CFA
WT-IFAPrior to testing on behavioral test days, the width of each hindpaw at theankle was measured with calipers, and the skin temperature of the plantar
surface of the paw was measured with an infrared thermometer (Fisher Sci-
entiﬁc). Swelling of the ankle and local ﬂair were recorded as percent change
in hindpaw width and skin temperature at various time points pre- and post-
injection. For histopathological evaluation, sections of ankles stained with
hematoxylin and safranin-O were examined on a Leitz DMR light micro-
scope; color photomicrographs were acquired with a Retiga EX camera
with an RGB ﬁlter (Q-imaging). From every joint preparation, 4e6 sections,
taken approximately 100 mm apart, were scored for severity of arthritis by
an investigator who was blinded to the genotype of the animal and the treat-
ment received40. The severity of AIA was scored according to the following
scale: 0 e normal, 1 e mild inﬂammation with minor histological changes,
2 e moderate inﬂammatory disease, 3 e marked inﬂammatory changes
with erosive arthritis and pannus formation, and 4 e severe destructive arthri-
tis with major bone remodeling. Mean scores for individual joints, derived
from scores for different sections of the same joint, were used to calculate
composite scores for the various experimental groups.10
n
c
y
 
(
s
)IMAGE ANALYSIS AND STATISTICS0
2
4
6
8
0 3 7 10 14 21
Time after injection (days)
P
a
w
 
w
i
t
h
d
r
a
w
a
l
 
l
a
t
e
Fig. 1. CFA-induced mechanical allodynia and thermal hyperalge-
sia were decreased in TRPV1-KO mice. (A) von Frey mechanical
testing showed that, compared to baseline sensitivity (time point
0), the CFA-injected side was signiﬁcantly more sensitive than
the IFA-injected side in both phenotypes. Also, the CFA-injected
side of KO mice was less sensitive compared to WT mice through-
out the testing period and this difference was statistically signiﬁcant
at 14 days. (B) The Hargreaves test showed signiﬁcantly
decreased withdrawal latencies compared to baselines on the
CFA-injected side of WT but not in KO mice.Digital images were analyzed using Image J 1.38x software (NIH) by an
investigator blinded to the source material, including the genetic makeup
of the mouse and the side (i.e., the notch identifying the right side in spinal
cord sections was blocked out from view and the images were ﬂipped hori-
zontally). For DRG, 12 sections were analyzed per side per mouse (4e8 sec-
tions of each of L4 and L5 ganglia, approximately 60 mm apart); neuronal
proﬁles (NP) were identiﬁed by their typical cellular morphology. The cut-
off brightness level (labeling density threshold) was determined by averaging
the integral brightness of three NP per section that were judged to be mini-
mally positive. All NP whose mean labeling density exceeded this threshold
were counted as positive. For spinal cord, four transverse sections of the
L4eL5 segments, spaced approximately 300 mm apart, were analyzed in
every mouse. p-ERK-positive neurons, identiﬁed by simultaneous labeling
with NeuN, were counted in the dorsal horn on each side, spinal laminae
were deﬁned based on relative densities of cells and ﬁbers in images
obtained with DIC optics41.
Data were analyzed using SPSS 11.5x software and graphed using
Microsoft Excel. Differences between behavioral measurements and of
immunohistochemical scores in different animal groups were studied for sig-
niﬁcance with one-way analysis of variance (ANOVA), which assessed the
overall inﬂuence of genotype, injected side, and time after induction of
AIA, followed by a post hoc general contrast comparison using Tukey’s
test. Analysis of the histological scores for severity of arthritis was performed
using nonparametric ManneWhitney U test. Signiﬁcance was set at
P< 0.05.Results
Baseline sensitivity to mechanical or thermal stimuli did
not differ signiﬁcantly between KO and WT mice (Fig. 1).
von Frey testing showed that, for all time points, the CFA-in-
jected side was signiﬁcantly more sensitive to mechanical
stimulation than the IFA-injected side for each genotype,
and that there was a slight increase in sensitivity on the
IFA-injected side of WT but not KO mice (Fig. 1A). Both
WT and KO mice were most sensitive on day 3 after CFA
but maintained signiﬁcant allodynia for the duration of the
experiment. KO mice were less allodynic than WT on both
CFA- and IFA-injected sides throughout the testing period;
however, the attenuation of allodynia on the CFA-injected
side was signiﬁcant only on day 14 after injection
(Fig. 1A). The Hargreaves test revealed that CFA
decreased the withdrawal latencies in both WT and KO
mice. In WT mice withdrawal latency decreased to its low-
est as early as 3 days post-injection and remained
unchanged until day 21, while in KO mice, the latency
progressively decreased for the duration of the experiment
(Fig. 1B). Importantly, the withdrawal latency on the CFA-
injected side in KO mice was not signiﬁcantly different
from baseline or from the IFA-injected side, but was signif-
icantly longer than that on the CFA-injected side of WT mice
(Fig. 1B).Outward signs of inﬂammation were similarly pronounced
in WT and KO mice: the paw was reddened and swollen 3
days after injection of CFA and some blistering and/or
cracking of the skin appeared in some mice at day 7 and
resolved by day 10e14. Redness and swelling of the skin
decreased with time but the ankle remained enlarged by
w5 mm (200%) and the skin temperature was elevated by
w3C throughout the experiment. Upon visual inspection,
the IFA-injected ankle appeared unaffected and was used
for weight bearing with better overall mobility than the
CFA-injected side. Microscopic examination of joint
sections revealed that 3e7 days after injection, the joints
appeared largely unaffected. However, after 14e21 days,
all CFA-injected joints showed clear histological signs of
arthritis and, particularly at day 21, partial destruction of car-
tilage and bone and widespread pannus invasion
(Fig. 2AeD). Histopathological scores were signiﬁcantly
higher on the CFA-injected side than on the IFA-injected
side in both WT and KO mice at all survival time points.
Moreover, at 14 and 21 days after injection, the histological
changes in CFA-injected ankles were signiﬁcantly less
severe in KO mice than in WT mice (Fig. 2E).
Fourteen and 21 days after induction of AIA, the fraction of
p-ERK-immunoreactive DRG neurons on the CFA-injected
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Fig. 2. Histopathological scores were lower in TRPV1-KO than in WT mice with AIA. (AeD) Staining with hematoxylin and safranin-O was
used to assess for changes in the articular cartilage (arrowheads) and for pannus invasion (p) of the tibia. More subtle microscopic changes
in the joint tissues, including inﬂammatory inﬁltration of the joint capsule, hypertrophy and cloning of chondrocytes, and disorganization/
ﬁbrillation of the joint cartilage, were also considered in assigning a composite histological score of the overall severity of arthritis. At 21
days, all CFA-injected joints showed obvious signs of advanced OA with partial destruction of cartilage and bone and widespread pannus
invasion. (E) At both 14 and 21 days, the overall histological scores (mean S.E.M., 14e18 sections per group) on the CFA-injected side
were signiﬁcantly lower in KO mice than in WT mice. Scale bar, 100 mm.
247Osteoarthritis and Cartilage Vol. 17, No. 2side of KO mice was signiﬁcantly smaller than that in WT
mice, and not signiﬁcantly different from the fraction on the
IFA-injected side (Fig. 3AeE). In parallel with the changes
in the DRG, the number of p-ERK-immunoreactive neurons
in the superﬁcial dorsal horn of WT mice was also increased
14 and 21 days after CFA injection. In KO mice, this overall
increase was signiﬁcantly smaller, and the number of p-
ERK-immunoreactive neurons on the CFA-injected side
was signiﬁcantly smaller than that on the CFA-injected side
of WT mice (Fig. 3FeJ). At shorter survival time points, the
expression of p-ERK in DRG and spinal cord neurons was
not signiﬁcantly different on the CFA-injected and IFA-in-
jected sides of WT and KO mice.Fourteen and 21 days after induction of arthritis, the fraction
of p-ERK-immunoreactive neurons in DRG was 3e4 fold
higher on the CFA-injected side than on the IFA-injected
side (Fig. 4). The fraction of TRPV1-immunoreactive DRG
neurons also increased bilaterally over the values in na€ıve
mice (39.4 0.9% at day 14 and 40.6 0.8% at day 21 vs
28.0 1.7% in na€ıve mice, mean S.E.M.). The neurons that
co-expressed p-ERK and TRPV1 constituted a signiﬁcantly
higher fraction of TRPV1-immunoreactive neurons on the
CFA-injected side than on the IFA-injected side (Fig. 4H).
Moreover, the fraction of p-ERK-immunoreactive neurons
that also expressed TRPV1 was signiﬁcantly higher on the
CFA-injected side than on the IFA-injected side (Fig. 4I),
WT
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Fig. 3. Expression of p-ERK in DRG and spinal dorsal horn was lower in TRPV1-KO than in WT mice with AIA. (AeE) In DRG, the fraction of
labeled neurons on the CFA-injected side in KO mice was signiﬁcantly smaller than that in WT mice, and not signiﬁcantly different from the
fraction on the IFA-injected side. (FeJ) In the spinal cord, the number of p-ERK-immunoreactive neurons on the CFA-injected side in KO mice
was signiﬁcantly smaller than that in WT mice. Photomicrographs are from sections of representative mice with 21 days survival. The insert in
(F) illustrates simultaneous immunostaining for p-ERK (red) and the neuronal marker NeuN (green), used to verify that cells in the spinal cord
that express p-ERK were neurons. Data in histograms are mean S.E.M. from 4 to 8 sections per mouse for DRG and four sections per mouse
for the spinal cord in 4e6 mice per time point. Scale bars, 100 mm in (AeI) and 20 mm in the inset in (F).
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preferentially in TRPV1-positive neurons.
Discussion
The main ﬁndings of this study are that 14e21 days after
ankle injection of CFA in the mouse, (1) the number of neu-
rons in DRG and spinal dorsal horn at L4eL5 that express
the activated form of ERK increased several fold; (2) this
increase occurred preferentially in TRPV1-positive DRG
neurons, and (3) TRPV1-KO mice had reduced nociceptive
behavior, severity of OA, and activation of ERK in sensory
neurons, compared to WT mice.
The hypothesis that TRPV1 is involved in inﬂammatory
hyperalgesia was originally supported by evidence that
mice lacking this receptor do not develop hyperalgesia to
a noxious heat 24 h after cutaneous inﬂammation42e44, and
that capsazepine, a selective TRPV1 antagonist, reverses
the development ofmechanical hyperalgesia in experimental
inﬂammation45. More recently, the use of transgenic mice to
explore the pathways essential to the pathogenesis of human
diseases has expanded to include arthritis46.
In the present study, the mechanical allodynia and thermal
hyperalgesia following CFA were reduced in KO, compared
toWTmice, in agreement with the results of previous studiesof mouse models18,20. However, Bolcskei et al.17 found no
differences between KO and WT mice in formalin-induced
nocifensive behavior, carrageenan-evoked inﬂammatory
mechanical hyperalgesia, and partial sciatic nerve lesion-in-
duced neuropathic mechanical hyperalgesia. In addition,
Walker et al.45 reported that pre-treatment with capsazepine
reversed the CFA-induced mechanical hyperalgesia in
guinea pigs but not in rats or mice. We found that KO mice
had normal mechanical sensitivity at baseline42 and signiﬁ-
cantly higher mechanoreceptive thresholds on the IFA-
injected side than WT mice. This is consistent with the idea
that CFA may exert contralateral effects on mechanical, but
not on thermal sensitivity, presumably via involvement of
supraspinal pathways47, and that this effect may be
TRPV1-dependant, as it is missing in KO mice. Keeble
et al.19 argued that this suggests an essential involvement
of TRPV1 in the control, by the central nervous system, of
the phenotypic changes of articular primary sensory neurons
during arthritis.
The fraction of p-ERK-positive neurons was higher on the
CFA-injected side than on the IFA-injected side inWT but not
in KO mice, suggesting that the activation of ERK in
nociceptive primary afferents in AIA may be mediated by
TRPV1. This is consistent with our previous observation
that activation of ERK in primary afferents was signiﬁcantly
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Fig. 4. Expression of p-ERK increased preferentially in TRPV1-positive neurons in DRG after CFA. (AeF) Photomicrographs from ganglia of
a representative mouse with 21 days survival, showing that DRG neurons of wild-type mice express p-ERK (red), TRPV1 (green) or p-ERK/
TRPV1 (yellow) after injections of CFA or IFA. (G) The fraction of p-ERK-immunoreactive neurons of total neurons was signiﬁcantly higher on
the CFA-injected side than on the IFA-injected side, 14 and 21 days after injections. The double-labeled p-ERK/TRPV1-immunoreactive neu-
rons constituted a signiﬁcantly higher fraction of TRPV1-immunoreactive neurons on the CFA-injected side than on the IFA-injected side (H)
and the fraction of p-ERK-immunoreactive neurons that also expressed TRPV1 was signiﬁcantly higher on the CFA-injected side (I). Data in
histograms are mean S.E.M. from 12 sections per side per mouse in 4e6 mice per time point. Scale bar, 100 mm.
249Osteoarthritis and Cartilage Vol. 17, No. 2higher after intraarticular injections of capsaicin than vehi-
cle48. Alternatively, it may be due to the decreased pain
and inﬂammation observed in KOmice and not directly linked
to TRPV1. It has been shown that both cutaneous and vis-
ceral inﬂammation leads to nociceptive-speciﬁc activation
of ERK in spinal neurons27,49,50. Thismay underlie themech-
anism of central sensitization at the level of the spinal neuron
that receives direct synaptic input from the primary afferent
nociceptor. The speciﬁc involvement of the ERK pathway
in the mechanism of central sensitization is not completely
understood but acutely, ERK may modulate excitability of
spinal neurons through an interaction with N-methyl D-
aspartate (NMDA) receptors51; chronically, ERK or a down-
stream product may translocate to the nucleus and regulate
transcription of genes involved in nociception such as the
neurokinin receptor (NK1)52,53. Since TRPV1 can mediate
the release of glutamate and substance P (SP)54,55 from
DRG neurons that can induce phosphorylation of ERK in spi-
nal cord neurons56, we speculate that the increase of p-ERK
in AIA may be due, at least in part, to a TRPV1-dependentrelease of glutamate and SP. Therefore, the reduced activa-
tion of ERK in spinal neurons of TRPV1-KOmicemay be due
to a decreased release of glutamate and SP.
Several recent studies have addressed the role of the ERK
pathway in inﬂammatory joint pain. Using a rat model of AIA,
Cruz et al.34 showed that movement of the inﬂamed joint in-
creased the number of p-ERK-positive neurons in the spinal
dorsal horn correlatedwith thedurationof arthritis. In amouse
model of collagen-induced arthritis, upregulation of p-ERK in
joints peaked with maximum inﬂammation, and pharmaco-
logical inhibition of the ERK pathway produced a profound
antiarthritic effect25. Similarly, attenuated activation of ERK
inmice with genetic deletion of the scaffold kinase KSR1 cor-
related with impaired development of arthritis36. Taken
together, these results support the idea that activation of
ERK plays an important role in chronic joint pain and that
its inhibitionmay provide a therapeutic target for arthritis. Pro-
viding a functional link between activation of ERK in neurons
and their expression of TRPV1, Firner et al.32 showed that
ERK phosphorylation is required for rapid facilitation of
250 Y. Chen et al.: Vanilloid receptor TRPV1-mediated phosphorylation of ERKcapsaicin-induced currents in DRG neurons and concluded
that the ERK cascade plays a vital role in the regulation of
the TRPV1-positive nociceptors’ sensitivity.
In the present study, the edema caused by ankle injections
ofCFA inKOmicewassimilar toWT, at variancewithprevious
reports18e20. The degree of involvement of extra-articular soft
tissues in a particular inﬂammatory model may be an impor-
tant determinant of overall swelling of the paw. This may
also be why intraplantar injection of vanilloid compounds
produced less paw swelling in TRPV1-KO mice42. The same
reasoning may apply to the discrepant ﬁndings regarding the
severity of the adjuvant-induced histological changes in the
articular and periarticular tissues: the cumulative histopathol-
ogy scores inKO, compared toWTmice,were found to be sig-
niﬁcantly lower in the present study and by Szabo et al.20 but
not different byBartonet al.18Thus,while the studies that have
utilized KOmice and/or pharmacological manipulations agree
that TRPV1 plays an important role in the hyperalgesic and
vascular components of OA, the inﬂuence of the deletion of
the TRPV1 gene on the inﬂammatory and degenerative com-
ponents of arthritis remains elusive.
Upregulation of TRPV1 in sensory neurons may represent
one mechanism of pain hypersensitivity in arthritis. In this
study, the fraction of TRPV1-positive DRG neurons in
arthritic mice was signiﬁcantly higher than that in na€ıve
mice. The value of comparing counts of immunopositive
neurons across different groups of animals may be limited
by the vagaries of the immunohistochemical protocols.
Moreover, we could not identify the articular afferents
from the injected ankles, and any discrete changes in this
restricted pool may have escaped our analysis. However,
our results are consistent with the report that 2 days after
injection of CFA in a mouse hindpaw, the percentage of
isolectin B4 of Griffonia simplicifolia (IB4)-positive DRG
neurons that responded to capsaicin or Hþ increased from
24% to 80% and from 54% to 85%, respectively, in parallel
with an increased number of TRPV1-immunoreactive
neurons57. Increased expression of TRPV1 has been
reported in DRG neurons58e61 and in peripheral nerve ﬁbers
at the site of inﬂammation62,63, although the changes in
TRPV1 expression may depend on the particular model of
arthritis, survival time, and animal species64.
Conclusion
In the present study, we have established that activation
of the ERK biochemical cascade in nociceptive neurons is
mediated, at least in part, by TRPV1. In the absence of
TRPV1, the signs of arthralgia and histopathology in the
mouse model of AIA are reduced. It will be important to
determine the extent of involvement of TRPV1 in ERK acti-
vation in nociceptive neurons and to further elucidate the
mechanism by which ERK mediates the development of
pain and inﬂammation in arthritis.Conﬂict of interest
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